We Think You Should Be Aware Of Some Concerning Factors In Shandong Polymer Biochemicals' (SZSE:002476) Earnings
We Think You Should Be Aware Of Some Concerning Factors In Shandong Polymer Biochemicals' (SZSE:002476) Earnings
Following the solid earnings report from Shandong Polymer Biochemicals Co., Ltd. (SZSE:002476), the market responded by bidding up the stock price. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.
寶莫股份發佈了可靠的業績報告(SZSE:002476),市場對其股價報價偏高做出了回應。雖然利潤數字表現不錯,但我們的分析發現了一些令股東們應該知悉的令人關注的因素。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
For anyone who wants to understand Shandong Polymer Biochemicals' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥26m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Shandong Polymer Biochemicals' positive unusual items were quite significant relative to its profit in the year to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
對於想要了解寶莫股份的利潤超出法定數字的人,重要的是要注意,在過去12個月中,法定利潤從2600萬人民幣的飛凡項目中獲益。雖然獲得更高的利潤總是件好事,但大部分來自飛凡項目的貢獻有時會減弱我們的熱情。 我們分析了全球大多數上市公司的數據,發現飛凡項目通常是一次性的。這是預料之中的,因爲這些提振被描述爲「飛凡」。我們可以看到,相對於2024年9月的盈利數據來說,寶莫股份的積極飛凡項目相當顯著。其他條件相同的情況下,這可能會導致法定利潤成爲衡量潛在盈利能力的不良指標。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shandong Polymer Biochemicals.
注意:我們始終建議投資者檢查資產負債表強度。點擊這裏查看我們對寶莫股份資產負債表分析。
Our Take On Shandong Polymer Biochemicals' Profit Performance
我們對寶莫股份利潤表現的看法
As previously mentioned, Shandong Polymer Biochemicals' large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Shandong Polymer Biochemicals' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Shandong Polymer Biochemicals, you'd also look into what risks it is currently facing. You'd be interested to know, that we found 1 warning sign for Shandong Polymer Biochemicals and you'll want to know about this.
正如之前提到的,寶莫股份受益於飛凡項目的大幅提升,這種情況不會持續無限期,因此其法定收益可能不是其潛在盈利能力的良好指南。因此,我們認爲寶莫股份的法定利潤可能不是其潛在盈利能力的良好指南,並且可能給投資者對公司產生過於樂觀的印象。光明面是,該公司今年盈利,與去年虧損形成鮮明對比。當然,在分析其收益時,我們僅是皮毛;人們也可以考慮毛利率、預測增長以及投資回報率等其他因素。如果您想深入了解寶莫股份,還需了解其當前面臨的風險。您可能會感興趣地了解,我們爲寶莫股份發現了1個警示信號,您可能會對此感興趣。
This note has only looked at a single factor that sheds light on the nature of Shandong Polymer Biochemicals' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
這份備註只針對了一個能揭示寶莫股份盈利性質的因素。不過,有很多其他方式可以爲您了解一家公司。一些人認爲高股東權益回報率是一家優質企業的良好跡象。因此,您可能希望查看這個免費的公司收藏,其中有很多公司擁有高股東權益回報率,或者查看這份擁有高內部持股的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。